19.10.2021 • NewsMerckCell Therapygene therapy

Germany’s Merck Expands CDMO Footprint

Germany’s Merck has opened its second production facility for viral vectors at Carlsbad, California, a move the company said significantly expands its global CDMO footprint. The new €100 million plant will more than double the company’s existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy.

Customers for the two plants’ output are pharmaceutical producers engaged in cell and gene therapy, a market Merck says is expected to grow to $10 billion by 2026, driven by the industry’s rapid adoption of viral vector-based therapies.

Between them, the two facilities have 30 cleanroom suites to support all aspects of manufacturing from small- to large-scale clinical and commercial production and are said to deploy cutting-edge suspension technology to enable scalable and cost-effective manufacturing.

Most gene therapies target rare diseases, but there is an urgent need to efficiently manufacture these treatments to reach larger patient populations,” said Matthias Heinzel, member of Merck’s managing board and CEO Life Science. As a leader in viral vector manufacturing, Heinzel said the company is increasing its capacity and scale to help drug development customers bring new curative treatments to market.

One of the first CDMOs to be granted approval for viral vector manufacturing from both the US Food and Drug Administration and European Medicines Agency, Merck has a background of nearly 30 years of experience in cell and gene therapy, which it said enables it to offer unique CDMO services.

The Darmstadt-based company said the production upgrade fits with its Life Science arm’s ambition to accelerate growth through investments in “Big 3” businesses. This includes plans to expand Process Solutions’ contract services for traditional and novel applications.

Author: Dede Williams, Freelance Journalist

Germany’s Merck has opened a second plant for viral vectors at Carlsbad,...
Germany’s Merck has opened a second plant for viral vectors at Carlsbad, California. The new €100 million facility will more than double its existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy and expand its CDMO footprint. © KATERYNA KON/SCIENCE PHOTO LIBRARY/Getty Images

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.